Alzamend Neuro

IPO

Making Alzheimer's Just a Memory

Public · Atlanta, United States

Headquarters
Atlanta, Georgia
Business Model
B2B
Type
Public
Ticker
ALZN · NASDAQ

About

Alzamend Neuro is a clinical-stage biopharmaceutical company that develops treatments for Alzheimer's disease and psychiatric disorders including bipolar disorder, major depressive disorder, and PTSD. Its pipeline includes AL001, a patented ionic cocrystal that delivers lithium via lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine designed to restore a patient's immune response against Alzheimer's-related amyloid-beta. Both candidates are licensed from the University of South Florida Research Foundation, and AL001 has advanced into Phase II Lithium in Brain trials with Massachusetts General Hospital.

Summary

Alzamend Neuro is a Biotech company based in Atlanta, United States.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Post-IPO EquityPost-IPO Convertible Preferred FinancingAug 2026
$7.5M

Sign up to see all 2 rounds

IPO through Post-IPO Equity — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alzamend Neuro on Indexed.vc
<a href="https://indexed.vc/companies/alzamend-neuro"><img src="https://indexed.vc/api/badge/company/alzamend-neuro" alt="Alzamend Neuro on Indexed.vc" width="260" height="76" /></a>